RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
Sun F, Wang X, Hu J, Liu J, Wang X, Jia W, Yu Z, Gao L, Dou B, Zhao R, Feng T, Wang X, Zhang W, Liu H, Liu K, Shao Y, Dong X, Han B.
Sun F, et al.
Oncogene. 2022 Jun;41(23):3239-3250. doi: 10.1038/s41388-022-02332-8. Epub 2022 May 4.
Oncogene. 2022.
PMID: 35508542